Pulmatrix Inc(PULM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:20 PM ET (Korea 10/1 05:20)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.1 | Insider Own | - | Shs Outstand | 3.6M | Perf Week | -9.79% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 3.6M | Perf Month | 3.4% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 9.16% | Short Float | 1.52% | Perf Quarter | -12.64% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 1.54% | Short Ratio | 2.09 | Perf Half Y | 17.83% |
| Sales | 0.00B | P/B | 3.49 | EPS next 5Y | - | ROA | -85.4% | Short Interest | 0.06M | Perf YTD | -31.84% |
| Book/sh | 0.44 | P/C | 1.94 | EPS past 3/5Y | 36.28% 36.26% | ROE | -98.35% | 52W High | -72.35% ($5.50) | Perf Year | -68.72% |
| Cash/sh | 0.79 | P/FCF | - | Sales past 3/5Y | - | ROIC | -156.94% | 52W Low | 31.03% ($1.16) | Perf 3Y | -25.12% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 49.19% | Gross Margin | - | Volatility(W/M) | 5.94% 6.64% | Perf 5Y | -90.5% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -99.54% |
| Dividend Ex-Date | - | Quick Ratio | 4.7 | EPS Q/Q | 32.09% | Profit Margin | - | RSI (14) | 47.78 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.7 | Sales Q/Q | - | SMA20 | 0.85% ($1.51) | Beta | 1.93 | Target Price | $10 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -3.05% ($1.57) | Rel Volume | 0.26 | Prev Close | $1.56 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -18.36% ($1.86) | Avg Volume(3M) | 0.03M | Price | $1.52 |
| IPO | 2014/3/21 | Option/Short | No/Yes | Trades | 67 | Volume | 7,021 | Change | -2.38% |
Pearl Bio (), or PearlMatrix, is a US clinical-stage biotech company that has been developing drug candidates targeting chronic obstructive pulmonary disease (COPD), fungal lung infections, and migraines, built around its proprietary inhalable dry powder formulation platform called 'iSPERSE.' It is a micro-cap stock with virtually no revenue, currently undergoing a business restructuring through mergers and asset divestitures.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded less than usual That is 26% of its average volume.
PULM has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -90.5%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #546 of 592 in the industry
Based on market cap of $6M.
FAQ
What kind of company is PULM?
PULM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PULM?
The market cap of PULM is approximately $6M, ranking 5,661 within its sector.
What is the 52-week high and low for PULM?
PULM has recorded a 52-week high of $5.50 and a low of $1.16.
